Plain-English translation of NCT06366724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The LIFT trial is testing whether two medications— and —can help reduce symptoms of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID, particularly orthostatic intolerance (dizziness when standing up). This is a double-blind study, meaning neither you nor the researchers will know which medication or placebo you're receiving. The goal is to find safe, effective treatment options for people living with these debilitating conditions.
ME/CFS and long COVID can cause severe fatigue, exercise intolerance, and dizziness—symptoms that dramatically reduce quality of life. Currently, there are very few proven treatment options. This trial exists to determine whether this medication combination could offer relief and improve daily functioning for patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
You will participate for approximately three months. You'll have three in-person visits to Brigham and Women's Hospital and four virtual visits. During the study, you'll take liquid medication by mouth—some participants receive the active medications, others receive placebos—with doses gradually increased over time. You'll complete two exercise tests (not strenuous), answer questionnaires online, and have blood and urine samples collected. The researchers will adjust your dose if you experience side effects, and you can scale back if needed. Weekly check-ins with the study team help ensure your safety and comfort.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States